Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 18F-JK-PSMA-7 vs 18F-fluorocholine PET/CT in biochemical recurrence of prostate cancer
2021-005993-24Phase 3Completed
- Sponsor
- ITEL Telecomunicazioni
- Start
- Sep 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of [18F]F-JK-PSMA-7 and fluorine-18 fluorocholine in prostate cancer (PCa) (2 arms), sponsored by ITEL Telecomunicazioni. Primary endpoint: Patient-based detection rate. Started Sep 2022; status: completed.
02
Drugs
[18F]F-JK-PSMA-7fluorine-18 fluorocholine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-005993-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005993-24.